2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
News
Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
Annual Report to Security Holders
Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
PRE 14A
Additional Proxy Soliciting Materials
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Confidential Treatment Order
Correspondence
Submission Upload